OFS Capital (NASDAQ:OFS – Get Free Report) and Advanced Medical Isotope (OTCMKTS:RDGL – Get Free Report) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Insider and Institutional Ownership
10.8% of OFS Capital shares are owned by institutional investors. 0.5% of OFS Capital shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for OFS Capital and Advanced Medical Isotope, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OFS Capital | 1 | 1 | 0 | 0 | 1.50 |
| Advanced Medical Isotope | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares OFS Capital and Advanced Medical Isotope’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OFS Capital | 7.52% | 8.95% | 3.41% |
| Advanced Medical Isotope | -6,144.90% | N/A | -113.56% |
Volatility & Risk
OFS Capital has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500.
Earnings and Valuation
This table compares OFS Capital and Advanced Medical Isotope”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OFS Capital | $47.96 million | N/A | $28.44 million | $0.24 | 21.13 |
| Advanced Medical Isotope | $30,000.00 | 1,038.53 | -$2.91 million | N/A | N/A |
OFS Capital has higher revenue and earnings than Advanced Medical Isotope.
Summary
OFS Capital beats Advanced Medical Isotope on 9 of the 10 factors compared between the two stocks.
About OFS Capital
OFS Capital Corporation is a business development company specializing in direct and fund investments as well as add-on acquisitions. It provides flexible capital solutions primarily through debt capital and to a lesser extent, minority equity investments serving the needs of U.S.-based middle-market companies across a broad array of industries. It does not invest in operational turnarounds or start-up businesses. For direct, it specializes in debt and structured equity investments, recapitalizations and refinancing, management and leveraged buyouts, acquisition financings, ownership transition, shareholder liquidity events, growth capital, independent sponsor transactions, ESOPs, and minority investments in the lower middle market companies. It invests in the aerospace and defense, business services, consumer products and services, construction & building, durable goods, capital equipment, automotive, food and beverage, healthcare & pharmaceutical, specialty chemicals, transportation cargo and logistics, value added distribution, franchising, and industrial and niche manufacturing sectors. The firm invests in companies based in United States. It seeks to invest between $3 million and $35 million, revenues between $15 million and $300 million, annual EBITDA between $5 million and $50 million, and Enterprise value between $10 million and $500 million. The firm seeks to invest in companies with debt investment values between $5 million and $25 million. The fund uses senior secured, unitranche loans, first-lien, second lien, subordinated/ mezzanine loans, warrants, and preferred equity securities and common equity securities. It prefers to take a minority as well as majority stake in the investments made. It also co-invests with its partners for additional capital.
About Advanced Medical Isotope
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Receive News & Ratings for OFS Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OFS Capital and related companies with MarketBeat.com's FREE daily email newsletter.
